---
title: "Tempus AI, Inc. (TEM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TEM.US.md"
symbol: "TEM.US"
name: "Tempus AI, Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-19T23:07:29.339Z"
locales:
  - [en](https://longbridge.com/en/quote/TEM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TEM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TEM.US.md)
---

# Tempus AI, Inc. (TEM.US)

## Company Overview

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.tempus.com](https://www.tempus.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: C (0.46)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 19 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 69.82% |  |
| Net Profit YoY | 57.94% |  |
| P/B Ratio | 18.79 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 7825629524.40 |  |
| Revenue | 1364168000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -81.58% | E |
| Profit Margin | -22.20% | D |
| Gross Margin | 63.78% | A |
| Revenue YoY | 69.82% | A |
| Net Profit YoY | 57.94% | B |
| Total Assets YoY | 38.36% | A |
| Net Assets YoY | 27.66% | A |
| Cash Flow Margin | 61.32% | C |
| OCF YoY | 69.82% | A |
| Turnover | 0.74 | B |
| Gearing Ratio | 80.50% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Tempus AI, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "69.82%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "57.94%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "18.79",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "7825629524.40",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1364168000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-81.58%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-22.20%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "63.78%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "69.82%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "57.94%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "38.36%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "27.66%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "61.32%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "69.82%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.74",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "80.50%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -25.83 | 51/59 | - | - | - |
| PB | 18.79 | 50/59 | 42.57 | 26.65 | 19.67 |
| PS (TTM) | 5.74 | 44/59 | 14.34 | 11.91 | 7.79 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **17**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 8 | 47% |
| Overweight | 2 | 12% |
| Hold | 6 | 35% |
| Sell | 1 | 6% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 45.53 |
| Highest Target | 100.00 |
| Lowest Target | 35.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TEM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TEM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TEM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TEM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**